Alnylam Pharmaceuticals, Biosaxony and BioInnovation Center Dresden, Cellectricon, and CytRx and Imperial College London

May 28, 2004

Premium

Alnylam Lowers Share Price Range for IPO

Alnylam Pharmaceuticals has lowered the range at which it expects its shares to float in a planned inital public offering to $5 to $8 per share from $10 to $12 per share, according to a company filing with the US Securities and Exchange Commission.

The company still intends on selling 5 million shares of its common stock through the offering, plus an additional 750,000 being offered to the IPO’s underwriters to cover over-allotments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Links Between Them

Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.

Retaliation Claim

The Verge details the account of an academic who alleges her university retaliated against her after she complained of sexual harassment by her supervisor.

Good Samples Under the Glass

The New York Times writes that natural history museums are helping round out genetic studies with older specimens.

This Week in PNAS

In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.

Featured White Papers

iPSC & CRISPR/Cas9 Technologies Enable Precise & Controlled Physiologically Relevant Disease Modeling for Basic & Applied Research

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Nov

15

Featured Webinar

Next-Generation Platforms for Strain Optimization: Reducing the Cost and Time for Commercializing Novel Biological Molecules

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.

Dec

03

Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec

04

Featured Webinar

Clinical-Grade Exome Analysis for Complex and Unsolved Case Investigations

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Main menu